BioSpace News Archive

Job Trends

Using AI for Gene Therapy Design, Dyno Scoops Up $100 Million to Expand Platform

Since emerging from stealth mode in 2020 Dyno Therapeutics has been busy advancing its gene therapy platform. This morning, the company bolsters its research with $100 million raised in a Series A financing round.

May 6, 2021
·
3 min read
·
Alex Keown
FDA

Merck’s Blockbuster Cancer Antibody Racks Up Another Approval

The U.S. FDA approved Keytruda combined with Genentech’s Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemotherapy, for first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

May 6, 2021
·
3 min read
·
Mark Terry
BioCapital

Current COVID-19 Vaccines Proving Efficacy Against New Variants

Newly-published studies suggest currently authorized COVID-19 vaccines may be effective for protecting against new and emerging variants of the novel coronavirus, while booster doses of these vaccines may improve the overall efficiencies of these immunizations at combating these variants.

May 6, 2021
·
4 min read
·
Brandon May
Drug Development

With Approvals in Hand, These Three New Drugs Are Hitting the Market

Less than two weeks after receiving the greenlight for Zynlonta under accelerated approval, ADC Therapeutics has launched its treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma.

May 6, 2021
·
3 min read
·
Alex Keown
Career Advice

Can Your Employer Make You Get a Vaccine? A Conversation with an HR Consultant

We interviewed Krissy Fuller, a human resources consultant, to learn more about the issue of mandated vaccines from an HR perspective and shared her predictions on what changes she thinks will last after the pandemic.

May 6, 2021
·
4 min read
·
Porschia Parker-Griffin
Drug Development

Rocky Road for Biogen’s Aducanumab Now Includes Pricing Hurdle

With Biogen’s potential treatment for Alzheimer’s, aducanumab, coming in weeks before a U.S. FDA decision, ICER wrote a punishing report slamming the drug for insufficient efficacy and recommending a low price point if approved.

May 6, 2021
·
4 min read
·
Mark Terry
Drug Development

Bluebird Bio Q1 Highlights: Abecma Launch, Clinical Holds, Spinout Name and More

Bluebird bio reported first-quarter earnings, the approval of Abecma, the first CAR-T therapy for relapsed or refractory multiple myeloma, and its spinout, 2seventy bio, and its leadership.

May 6, 2021
·
3 min read
·
Mark Terry
Business

Get to Know Jonathan Rigby, Group CEO of Revolo Biotherapeutics

BioSpace recently spoke with Jonathan Rigby, Group CEO of Revolo Biotherapeutics, a biotherapeutic company working to revolutionize the treatment of autoimmune and allergic disease by achieving superior long-term disease remission through resetting the immune system.

May 6, 2021
·
4 min read
·
Gina Hagler
Drug Development

Research Roundup: Genetics of People Older than 105 and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

May 6, 2021
·
5 min read
·
Mark Terry
Deals

Two Companies Growing via Acquisitions this Week

Two new notable biotech/biopharma acquisitions were reported this week: Athenex has acquired Kuur Therapeutics, while Altasciences has acquired preclinical CRO Calvert Laboratories.

May 6, 2021
·
2 min read
·
Brandon May